This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrillo, A.
Right arrow Articles by Molla, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrillo, A.
Right arrow Articles by Molla, A.

 Previous Article  |  Next Article 

Journal of Virology, September 1998, p. 7532-7541, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor

Alejandro Carrillo,* Kent D. Stewart, Hing L. Sham, Daniel W. Norbeck, William E. Kohlbrenner, John M. Leonard, Dale J. Kempf, and Akhteruzzaman Molla

Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064

Received 31 March 1998/Accepted 4 June 1998

ABT-378, a new human immunodeficiency virus type 1 (HIV-1) protease inhibitor which is significantly more active than ritonavir in cell culture, is currently under investigation for the treatment of AIDS. Development of viral resistance to ABT-378 in vitro was studied by serial passage of HIV-1 (pNL4-3) in MT-4 cells. Selection of viral variants with increasing concentrations of ABT-378 revealed a sequential appearance of mutations in the protease gene: I84V-L10F-M46I-T91S-V32I-I47V. Further selection at a 3.0 µM inhibitor concentration resulted in an additional change at residue 47 (V47A), as well as reversion at residue 32 back to the wild-type sequence. The 50% effective concentration of ABT-378 against passaged virus containing these additional changes was 338-fold higher than that against wild-type virus. In addition to changes in the protease gene, sequence analysis of passaged virus revealed mutations in the p1/p6 (P1' residue Leu to Phe) and p7/p1 (P2 residue Ala to Val) gag proteolytic processing sites. The p1/p6 mutation appeared in several clones derived from early passages and was present in all clones obtained from passage P11 (0.42 µM ABT-378) onward. The p7/p1 mutation appeared very late during the selection process and was strongly associated with the emergence of the additional change at residue 47 (V47A) and the reversion at residue 32 back to the wild-type sequence. Furthermore, this p7/p1 mutation was present in all clones obtained from passage P17 (3.0 µM ABT-378) onward and always occurred in conjunction with the p1/p6 mutation. Full-length molecular clones containing protease mutations observed very late during the selection process were constructed and found to be viable only in the presence of both the p7/p1 and p1/p6 cleavage-site mutations. This suggests that mutation of these gag proteolytic cleavage sites is required for the growth of highly resistant HIV-1 selected by ABT-378 and supports recent work demonstrating that mutations in the p7/p1/p6 region play an important role in conferring resistance to protease inhibitors (L. Doyon et al., J. Virol. 70:3763-3769, 1996; Y. M. Zhang et al., J. Virol. 71:6662-6670, 1997).

* Corresponding author. Mailing address: D-7BP, Strategic Technical Product Development, Building AP8B, Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, IL 60064. Phone: (847) 937-3179. Fax: (847) 938-3721. E-mail: alex.carrillo{at}add.ssw.abbott.com.

Journal of Virology, September 1998, p. 7532-7541, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Shahriar, R., Rhee, S.-Y., Liu, T. F., Fessel, W. J., Scarsella, A., Towner, W., Holmes, S. P., Zolopa, A. R., Shafer, R. W. (2009). Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations. Antimicrob. Agents Chemother. 53: 4869-4878 [Abstract] [Full Text]  
  • de Campos, W. R. L., Coopusamy, D., Morris, L., Mayosi, B. M., Khati, M. (2009). Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals. Antimicrob. Agents Chemother. 53: 3056-3064 [Abstract] [Full Text]  
  • Aoki, M., Venzon, D. J., Koh, Y., Aoki-Ogata, H., Miyakawa, T., Yoshimura, K., Maeda, K., Mitsuya, H. (2009). Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors. J. Virol. 83: 3059-3068 [Abstract] [Full Text]  
  • Dekhtyar, T., Ng, T. I., Lu, L., Masse, S., DeGoey, D. A., Flosi, W. J., Grampovnik, D. J., Klein, L. L., Kempf, D. J., Molla, A. (2008). Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742. Antimicrob. Agents Chemother. 52: 1337-1344 [Abstract] [Full Text]  
  • Coren, L. V., Thomas, J. A., Chertova, E., Sowder, R. C. II, Gagliardi, T. D., Gorelick, R. J., Ott, D. E. (2007). Mutational Analysis of the C-Terminal Gag Cleavage Sites in Human Immunodeficiency Virus Type 1. J. Virol. 81: 10047-10054 [Abstract] [Full Text]  
  • Masse, S., Lu, X., Dekhtyar, T., Lu, L., Koev, G., Gao, F., Mo, H., Kempf, D., Bernstein, B., Hanna, G. J., Molla, A. (2007). In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir. Antimicrob. Agents Chemother. 51: 3075-3080 [Abstract] [Full Text]  
  • Girnary, R., King, L., Robinson, L., Elston, R., Brierley, I. (2007). Structure-function analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors. J. Gen. Virol. 88: 226-235 [Abstract] [Full Text]  
  • Brann, T. W., Dewar, R. L., Jiang, M.-K., Shah, A., Nagashima, K., Metcalf, J. A., Falloon, J., Lane, H. C., Imamichi, T. (2006). Functional Correlation between a Novel Amino Acid Insertion at Codon 19 in the Protease of Human Immunodeficiency Virus Type 1 and Polymorphism in the p1/p6 Gag Cleavage Site in Drug Resistance and Replication Fitness.. J. Virol. 80: 6136-6145 [Abstract] [Full Text]  
  • Prabu-Jeyabalan, M., King, N. M., Nalivaika, E. A., Heilek-Snyder, G., Cammack, N., Schiffer, C. A. (2006). Substrate Envelope and Drug Resistance: Crystal Structure of RO1 in Complex with Wild-Type Human Immunodeficiency Virus Type 1 Protease.. Antimicrob. Agents Chemother. 50: 1518-1521 [Abstract] [Full Text]  
  • Rodes, B., Sheldon, J., Toro, C., Jimenez, V., Alvarez, M. A., Soriano, V. (2006). Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 57: 709-713 [Abstract] [Full Text]  
  • Yates, P. J., Hazen, R., St. Clair, M., Boone, L., Tisdale, M., Elston, R. C. (2006). In Vitro Development of Resistance to Human Immunodeficiency Virus Protease Inhibitor GW640385. Antimicrob. Agents Chemother. 50: 1092-1095 [Abstract] [Full Text]  
  • Weinheimer, S., Discotto, L., Friborg, J., Yang, H., Colonno, R. (2005). Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of Increased Susceptibility to Other Protease Inhibitors in a Variety of Human Immunodeficiency Virus Type 1 Genetic Backbones. Antimicrob. Agents Chemother. 49: 3816-3824 [Abstract] [Full Text]  
  • Mo, H., King, M. S., King, K., Molla, A., Brun, S., Kempf, D. J. (2005). Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates. J. Virol. 79: 3329-3338 [Abstract] [Full Text]  
  • Bouchonnet, F., Dam, E., Mammano, F., de Soultrait, V., Hennere, G., Benech, H., Clavel, F., Hance, A. J. (2005). Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues. J. Virol. 79: 812-822 [Abstract] [Full Text]  
  • Roudinskii, N. I., Sukhanova, A. L., Kazennova, E. V., Weber, J. N., Pokrovsky, V. V., Mikhailovich, V. M., Bobkov, A. F. (2004). Diversity of Human Immunodeficiency Virus Type 1 Subtype A and CRF03_AB Protease in Eastern Europe: Selection of the V77I Variant and Its Rapid Spread in Injecting Drug User Populations. J. Virol. 78: 11276-11287 [Abstract] [Full Text]  
  • Myint, L., Matsuda, M., Matsuda, Z., Yokomaku, Y., Chiba, T., Okano, A., Yamada, K., Sugiura, W. (2004). Gag Non-Cleavage Site Mutations Contribute to Full Recovery of Viral Fitness in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 444-452 [Abstract] [Full Text]  
  • Koh, Y., Nakata, H., Maeda, K., Ogata, H., Bilcer, G., Devasamudram, T., Kincaid, J. F., Boross, P., Wang, Y.-F., Tie, Y., Volarath, P., Gaddis, L., Harrison, R. W., Weber, I. T., Ghosh, A. K., Mitsuya, H. (2003). Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro. Antimicrob. Agents Chemother. 47: 3123-3129 [Abstract] [Full Text]  
  • Paulsen, D., Elston, R., Snowden, W., Tisdale, M., Ross, L. (2003). Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects. J Antimicrob Chemother 52: 319-323 [Full Text]  
  • Wu, T. D., Schiffer, C. A., Gonzales, M. J., Taylor, J., Kantor, R., Chou, S., Israelski, D., Zolopa, A. R., Fessel, W. J., Shafer, R. W. (2003). Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments. J. Virol. 77: 4836-4847 [Abstract] [Full Text]  
  • Aslanzadeh, J. (2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science 32: 406-413 [Abstract] [Full Text]  
  • Maguire, M. F., Guinea, R., Griffin, P., Macmanus, S., Elston, R. C., Wolfram, J., Richards, N., Hanlon, M. H., Porter, D. J. T., Wrin, T., Parkin, N., Tisdale, M., Furfine, E., Petropoulos, C., Snowden, B. W., Kleim, J.-P. (2002). Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro. J. Virol. 76: 7398-7406 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
  • Maguire, M., Shortino, D., Klein, A., Harris, W., Manohitharajah, V., Tisdale, M., Elston, R., Yeo, J., Randall, S., Xu, F., Parker, H., May, J., Snowden, W. (2002). Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors. Antimicrob. Agents Chemother. 46: 731-738 [Abstract] [Full Text]  
  • Dauber, D. S., Ziermann, R., Parkin, N., Maly, D. J., Mahrus, S., Harris, J. L., Ellman, J. A., Petropoulos, C., Craik, C. S. (2002). Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease. J. Virol. 76: 1359-1368 [Abstract] [Full Text]  
  • Kempf, D. J., Isaacson, J. D., King, M. S., Brun, S. C., Xu, Y., Real, K., Bernstein, B. M., Japour, A. J., Sun, E., Rode, R. A. (2001). Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients. J. Virol. 75: 7462-7469 [Abstract] [Full Text]  
  • Bleiber, G., Munoz, M., Ciuffi, A., Meylan, P., Telenti, A. (2001). Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 75: 3291-3300 [Abstract] [Full Text]  
  • Côté, H. C. F., Brumme, Z. L., Harrigan, P. R. (2001). Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir. J. Virol. 75: 589-594 [Abstract] [Full Text]  
  • Ikezoe, T., Daar, E. S., Hisatake, J.-i., Taguchi, H., Koeffler, H. P. (2000). HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 96: 3553-3559 [Abstract] [Full Text]  
  • Martinez-Picado, J., DePasquale, M. P., Kartsonis, N., Hanna, G. J., Wong, J., Finzi, D., Rosenberg, E., Gunthard, H. F., Sutton, L., Savara, A., Petropoulos, C. J., Hellmann, N., Walker, B. D., Richman, D. D., Siliciano, R., D'Aquila, R. T. (2000). Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. USA 97: 10948-10953 [Abstract] [Full Text]  
  • Gong, Y.-F., Robinson, B. S., Rose, R. E., Deminie, C., Spicer, T. P., Stock, D., Colonno, R. J., Lin, P.-f. (2000). In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632. Antimicrob. Agents Chemother. 44: 2319-2326 [Abstract] [Full Text]  
  • Yoshimura, K., Kato, R., Yusa, K., Kavlick, M. F., Maroun, V., Nguyen, A., Mimoto, T., Ueno, T., Shintani, M., Falloon, J., Masur, H., Hayashi, H., Erickson, J., Mitsuya, H. (1999). JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. USA 96: 8675-8680 [Abstract] [Full Text]  
  • Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanonda, S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, V., Grabowski, B., Granneman, G. R., Sun, E., Japour, A. J., Leonard, J. M., Plattner, J. J., Norbeck, D. W. (1998). ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease. Antimicrob. Agents Chemother. 42: 3218-3224 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»